Inizio's Elaine Ferguson on why enabling purpose-driven employees to make a meaningful difference is as important as any formal talent strategy.
Feature|Articles|September 22, 2026
The Most Expensive CI Failure is Missing the Moment Your Strategic Assumption Became Wrong
Author(s)Rafaat Rahmani
The best CI partner isn't the one with the most data — it's the one willing to tell you your assumptions are wrong.
Advertisement
Advertisement
Pharma companies are heading into another competitive intelligence (CI) request for proposal (RFP) season as they finalize 2027 budgets and reassess their external partners. At the same time, CI leaders are being asked to do more with increasingly sophisticated technology and overwhelming amounts of data, often while working with fewer external CI vendors.
Related to this article
As GLP-1 competition shifts from molecules to prescriptions, manufacturers, pharmacies, providers, and payers are racing to own the patient journey.
Life sciences liability risks change character — not just size — as companies move from R&D to commercialization.
Inizio's Elaine Ferguson on how cross-functional leadership pods tackling real business challenges are turning talent development into operational innovation.
How the shifting tides in information consumption are resetting expectations for pharma in providing and delivering health education.
CGT commercial trajectories are set years before approval — and every development decision is an access decision.
Inizio's Elaine Ferguson on why AI value requires deconstructing workflows task by task — aligning each to the right combination of talent and technology.
Pharma brands with all the right information are still invisible to AI — and why silence is the bigger risk than inaccuracy.
Advertisement
Advertisement